Risk of Ocular Hypertension With Intravitreal Triamcinolone Compared to the Dexamethasone Implant
Apoorv P Chebolu, Yineng Chen, Fangming Jin, Brian L VanderBeek · 2026
Read Risk of Ocular Hypertension With Intravitreal Triamcinolone Compared to the Dexamethasone Implant by Apoorv P Chebolu, Yineng Chen, Fangming Jin, Brian L VanderBeek (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13216112.txt.
Description
Apoorv P Chebolu and co-authors present a 2026 database study comparing two steroid treatments injected into the eye for their risk of raising eye pressure. One is a slow-release dexamethasone implant; the other is triamcinolone given as a standard injection.
Records from 2011 to 2022 covered 1,665 implant patients and 3,866 injection patients having their first such treatment. Pressure-related treatment was needed by 8.8 percent of the implant group and 7.3 percent of the injection group. After statistical balancing, risk was similar during the first forty days, then ran higher for the implant group beyond that point. The authors advise clinicians to weigh this later pressure risk when counselling patients.
Catalog record
| CREATOR | Apoorv P Chebolu, Yineng Chen, Fangming Jin, Brian L VanderBeek |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |